96 patents
Page 5 of 5
Utility
Inhibiting CREB binding protein (CBP)
21 Dec 20
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson
Filed: 27 Jun 19
Utility
SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZINE-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
16 Dec 20
George P. LUKE, Stephen HUBBS, Matthew W. MARTIN, Shawn E.R. SCHILLER, Robert WENSLOW, Yawei SHI, Jun HUANG
Filed: 27 Aug 20
Utility
Tetrahydroquinoline Compositions As Bet Bromodomain Inhibitors
25 Nov 20
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
Filed: 27 Jan 20
Utility
Compositions for activating pyruvate kinase
16 Nov 20
Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
Filed: 3 Oct 19
Utility
Compounds and Compositions for Inhibition of Fasn
4 Nov 20
Kenneth W. Bair, David R. Lancia, JR., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
Filed: 19 May 20
Utility
Alpha-cinnamide Compounds and Compositions As HDAC8 Inhibitors
21 Oct 20
The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
Kenneth W. Bair, Nicholas Barczak, Bingsong Han, David R. Lancia, JR., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Mary-Margaret Zablocki, Xiaozhang Zheng
Filed: 19 Nov 19
Utility
Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
19 Oct 20
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Filed: 21 Jul 19
Utility
Compounds and compositions for inhibition of FASN
12 Oct 20
Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
Filed: 9 Sep 19
Utility
Inhibiting Ubiquitin Specific Peptidase 30
7 Oct 20
The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities.
Justin Caravella, Bingsong Han, Cuixian Liu, Stephanos Ioannidis, Alexandre Joseph Buckmelter, David James Richard, Matthew W. Martin, Steven Mischke, Scot Mente
Filed: 4 Oct 18
Utility
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
5 Oct 20
George P. Luke, Stephen Hubbs, Matthew W. Martin, Robert Wenslow, Yawei Shi, Jun Huang
Filed: 28 Oct 19
Utility
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
23 Sep 20
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Patrick F. Kelly, Susan Ashwell
Filed: 3 Jun 20
Utility
Inhibiting Creb Binding Protein (CBP)
23 Sep 20
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson
Filed: 7 Jun 20
Utility
Activating Pyruvate Kinase R
12 Aug 20
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
Filed: 30 Apr 20
Utility
PYRIDIN-2(1H)-ONE Quinolinone Derivatives As Mutant-isocitrate Dehydrogenase Inhibitors
15 Jul 20
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
Filed: 11 Dec 19
Utility
Tetrahydro-imidazo Quinoline Compositions As CBP/P300 Inhibitors
8 Jul 20
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
Filed: 13 Sep 18
Utility
Benzopiperazine compositions as BET bromodomain inhibitors
6 Jul 20
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
Filed: 17 Jun 19